Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, January 5th. The firm currently has a $11.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 3.29% from the company’s current price.
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Several other brokerages have also issued reports on SYRS. JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a report on Thursday, September 28th. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. ValuEngine lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Oppenheimer set a $28.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 13th. Finally, Roth Capital began coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $22.23.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.08 during trading hours on Friday, hitting $10.65. The company had a trading volume of 270,500 shares, compared to its average volume of 252,275. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38. The stock has a market capitalization of $280.06 and a price-to-earnings ratio of -6.12.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). equities analysts anticipate that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In other Syros Pharmaceuticals news, Director Srinivas Akkaraju acquired 109,774 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were acquired at an average cost of $9.03 per share, for a total transaction of $991,259.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was acquired at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of SYRS. Nationwide Fund Advisors increased its stake in shares of Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Syros Pharmaceuticals in the third quarter worth about $133,000. Cubist Systematic Strategies LLC bought a new position in shares of Syros Pharmaceuticals in the third quarter worth about $149,000. The Manufacturers Life Insurance Company increased its stake in shares of Syros Pharmaceuticals by 11,253.8% in the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after purchasing an additional 10,466 shares during the period. Finally, Rhumbline Advisers bought a new position in shares of Syros Pharmaceuticals in the second quarter worth about $198,000. Institutional investors and hedge funds own 57.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/12/syros-pharmaceuticals-syrs-lifted-to-buy-at-zacks-investment-research.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.